Skip to content

Satellite Symposia

To provide additional educational opportunities at AMCP 2020, AMCP also allows non-commercial, grant-supported satellite symposia in conjunction with the meeting. These continuing education activities are developed by medical education organizations. Satellite Symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit. All Satellite Symposia will be held at the George R. Brown Convention Center. Any pre-registration taken for these activities is for planning purposes only and does not guarantee a seat. Seating is limited and provided on a first-come, first-served basis. We recommend an early arrival. For additional information about a specific symposium, please contact the program manager listed.

Tuesday, April 21 | 11:00 am – 1:00 pm


SS1: The Gene Therapy Transformation: A Guide for Managed Care Decision Makers | Room:  381

Jointly provided by Postgraduate Institute for Medicine and Impact Education, LLC®. Supported by independent educational grants from bluebird bio and BioMarin. Continuing education credit available for pharmacists and physicians.

Program Description

Although gene therapy is a promising treatment option for a number of diseases (including inherited disorders, some types of cancer, and certain viral infections), the technique remains risky and is still under investigation to ensure safety and efficacy. Furthermore, research in this field is particularly challenging given the inherent nature of rare diseases and genetic disorders. Approximately 30 million individuals in the United States are living with a rare disease, which by definition have a prevalence of 200,000 or fewer cases in the United States.

Genetic disorders and other rare diseases present unique challenges for health insurers in terms of requisite clinical intervention, disease management, and economic burden. The treatment landscape in US health care has already evolved significantly over the past several decades and appears to be on the precipice of its most groundbreaking innovation to date gene therapy. This program is designed to address the educational needs for payers and managed care professionals regarding the solutions necessary to address the unique clinical and financial considerations surrounding gene therapies that will ensure quality care and appropriate patient access.

Program Manager
Steven Casebeer, MBA
Steve.casebeer@impactedu.net

No fee registration: Click Here

SS2:  Debating Approaches to Atopic Dermatitis Treatment Across the Lifespan | Room:  382

Provided by PRIME Education, LLC. Supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. Continuing education credit available for pharmacists, physicians, and nurses.

Program Description

The field of AD is rapidly transforming with the recent approvals of novel targeted therapies, along with a variety of additional agents under development for children, adolescents, and adults. In the face of this evolving treatment paradigm, managed care professionals are confronted with new challenges regarding decisions for patients with this often-debilitating condition. Join a diverse panel of experts in allergy-immunology, dermatology, family medicine, and managed care at this symposium as they examine recent evidence and provide practical advice for optimizing outcomes for patients with AD from childhood through adulthood.

Don’t miss:

  • The latest evidence and treatment guidelines, including new data from AAD and AAAAI
  • A deep dive into novel targeted therapies for AD and their efficacy, safety, and patient-reported outcomes
  • Reviews of case-based scenarios to sharpen your skills in decision-making for complex patients
  • Q&A with renowned experts in AD and managed care

Program ManagerJill Friedman
j.friedman@primeinc.org

No fee registration: Click Here

Tuesday, April 21 | 6:00 pm – 8:00 pm


SS3: Navigating Changes in Clostridioides difficile Prevention and Treatment | Room:  381

Provided Jointly by Academy of Managed Care Pharmacy (AMCP) and Prime Education, LLC. Supported by an independent educational grant from Ferring Pharmaceuticals, Inc. Continuing education credit available for pharmacists, physicians and nurses.

Program Description

Clostridioides difficile (C. diff, previously known as Clostridium difficile) infections are a major health care concern. The Centers for Disease Control and Prevention (CDC) estimates that C. diff causes almost half a million illnesses in the U.S. yearly, and approximately 1 in 5 patients with a C. diff infection will experience one or more recurrent infections. There have been noteworthy advances in the development of C. diff infection prevention and treatment, including a growth in the understanding of the role a patient’s gut microbiome plays.

This session will look at the updated C. diff guidelines, the role a patient’s microbiome plays in new and recurrent infections, pipeline medications, and the potential impact of these new changes on managed care.

Program Manager
Julia Veeder
jveeder@amcp.org

No fee registration: Click Here

SS4: Collaborative Care™ – COPD in Managed Care: The Clinical and Utilization Benefits of Exacerbation Prevention | Room:  382

Provided jointly by Global Education Group and Integritas Communications.
Supported by an independent educational grant from AstraZeneca. Continuing education credit available for pharmacists and physicians.

Program Description

The biopsychosocial and economic impact of COPD is substantial. Preventing exacerbations by optimizing the delivery of COPD care across the healthcare continuum is imperative to achieving the ultimate goal of improved patient outcomes. This engaging program will assemble a multidisciplinary faculty panel consisting of a pulmonologist, primary care physician, and a managed care pharmacist to provide expert insights and discuss best practices in the management of COPD—including exacerbation risk prevention, available and emerging therapeutic options—and how these factors may be used to shape managed care pharmacy decisions and future managed care paradigms. Pertinent patient case studies will also be utilized to provide examples of how recommended approaches to evidence and value-based care can be collaborative applied to healthcare systems.

Program Manager
Christa Master
cmaster@integritasgrp.com

No Fee Registration: Click Here

Wednesday, April 22 | 6:00 am – 8:00 am


SS5:  Immunotherapy in the Treatment Arsenal for Small Cell Lung Cancer, and Implications for the “Four Ps” in Managed Care Settings-Patient, Provider, Pharmacy, and Plan | Room:  382

Provided by Medical Learning Institute, Inc.This activity is supported by an independent educational grant from AstraZeneca. Continuing education credit available for pharmacists, physicians and nurses.

Program Description

For over three decades, almost no treatment advances were made in small cell lung cancer (SCLC) until the checkpoint inhibitors finally propelled the SCLC treatment landscape forward with several recent regulatory approvals. More developments are expected in the near future on the SCLC treatment landscape.

This PeerView Live MasterClass and Practicum symposium will provide managed care professionals with a foundational overview of how cancer immunotherapies work and why/how this class of agents is different from other agents used in oncology, why they have revolutionized the management of cancer over the last few years, and how the management of SCLC is finally changing as a result of these therapies. In addition, the latest research and practical considerations for value assessment of cancer immunotherapies in managed care settings will be presented, with specific implications for SCLC. Practical guidance will be provided for incorporating the latest clinical advances in immuno-oncology related to SCLC into benefit design, seamless drug distribution and dispensing, maximal patient safety, and effective communication with patients and care team clinicians.

Program Manager
Margaret Walker
m.walker@peerview.com

No fee registration: Click Here

SS6:  Managing the Cost of C. Difficile Infection: Are You Spending More Than You Know? | Room:  381

Jointly provided Medical Education Resources, Inc and Impact Education, LLC®. Supported by an independent educational grant from Merck & Co., Inc. Continuing education credit available for pharmacists and physicians.

Program Description

The incidence of Clostridioides difficile infection or CDI, has increased over the past 2 decades. CDI differs from most other infections because it generally occurs after treatment with antimicrobial therapy. Some of the most commonly associated agents that CDI is associated with include clindamycin, ampicillin, cephalosporins, and fluoroquinolones. It is estimated that CDI costs the U.S. health care system $6 billion every year and average costs per case are more than $20,000.

A CDI expert will review treatment options and engage in peer-to-peer dialogue regarding recent developments and therapeutic recommendations. In addition, the faculty panel, including managed care experts, will review guideline-based recommendations to elucidate avoidable costs related to the management of CDI that may impact benefit design and coverage decision-making. Real-world case scenarios will be used to illustrate managed care best practices to evaluate all facets of medical and pharmacy management with initial and recurrent CDI, including assessment of existing and emerging therapies, and appropriate care management strategies to improve overall clinical and economic outcomes.

Program Manager
Steven Casebeer, MBA
Steve.casebeer@impactedu.net

No fee registration: Click Here

Thursday, April 23 | 6:00 am – 8:00 am


SS7:  Wet Age-Related Macular Degeneration: Advances in the Treatment Landscape | Room: 381

Provided by Pharmacy Times Continuing Education. Supported by an independent educational grant from Genentech. Continuing educational credit available for pharmacists.

Program Description

Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in the United States. In AMD, irreversible destruction of the macula leads to loss of fine-detail “straight ahead” vision required to read, drive, and recognize faces. AMD can progress quickly, with vision deteriorating within days of clinical manifestation. Over the past 15 years, intravitreal anti-vascular endothelial growth factor (VEGF) agents have revolutionized the management of neovascular AMD and preserved the vision of millions of Americans. Improvements in vision preservation and quality of life come with a cost—regular office visits for monitoring and intravitreal anti-VEGF injections, and financial strain. This activity features a retina specialist and managed care expert and will review the pathophysiology and burden of wet AMD, advances in diagnosis and monitoring, current and emerging therapies, economic considerations, and management strategies.

Program Manager
Crissy Wilson
cwilson@pharmacytimes.com

No fee registration: Click Here

SS8:  Precision Medicine in NSCLC: Real-World Applications of Testing & Treatment for the Managed Care Pharmacist | Room:  382

Provided by Creative Educational Concepts. Supported by an independent educational grant from AstraZeneca. Continuing education credit available for pharmacists and physicians.

Program Description

The last decade has seen expanded use of biomarker testing in non-small cell lung cancer (NSCLC) and a growing field of targeted therapies that have transformed the treatment landscape of advanced disease. The pace of changes in the field makes it difficult to translate the latest trial data and guideline recommendations into real-world practice. Gaps in appropriate testing or treatment can dramatically diminish survival gains seen in major cancer centers.

Managed care and specialty pharmacists will work through case scenarios involving the latest guideline recommendations for biomarker testing, currently available targeted therapies, and approaches to consider when balancing the cost and value of precision medicine. Use of audience response keypads and interactive case discussions will provide a lively forum for engagement for this important topic.

Program Manager
Ashley Lilly
www.ceconcepts.com

No fee registration: Click Here

Thursday, April 23 | 6:00 pm – 8:00 pm


SS9:  ManagedCareCGM.com Presents: The Value of Continuous Glucose Monitoring in the Advancement of Diabetes Care | Room:  381

Provided jointly by Medical Education Resources, Inc. and Impact Education, LLC®. Supported by an independent educational grant from Dexcom. Continuing education credit available for pharmacists and physicians.

Program Description

The vast majority of plan members with diabetes have an A1C above ADA targets, putting them at risk for other costly comorbidities. To effectively address these clinical challenges and elicit improvements across 29 indices of glycemic control and glycemic variability, continuous glucose monitoring (CGM) has been endorsed by various professional endocrinology-centered organizations. In 2017, the Centers for Medicare and Medicaid Services (CMS) Medicare made a milestone ruling, establishing benefit coverage for “therapeutic” CGM — a designation applying to those CGM systems approved for use in making treatment decisions without a fingerstick (non-adjunctive use). This program will elucidate the burden of diabetes and describe multifaceted clinical and administrative strategies across the medical and pharmacy benefits to promote quality care and manage costs while improving outcomes for affected plan members.

Program Manager
Steven Casebeer, MBA
Steve.casebeer@impactedu.net

No fee registration: Click Here

SS10:  Economic and Clinical Outcomes Assessment of Immuno-Oncology Agents: A Guide for Payer Decision Makers | Room:  382

Jointly provided by Postgraduate Institute for Medicine and Impact Education, LLC®. Supported by independent educational grants from Bristol-Myers Squibb and Merck & Co., Inc. Continuing education credit available for pharmacists and physicians.

Program Description

The advent and rapid escalation of targeted cancer therapies has led to the emergence of sophisticated immuno-oncology agents. However, the historically high cost of these agents has compelled payers to initiate strategies to control utilization and manage costs. Because of the explosive growth of this category and their corresponding budgetary impact, health care decision makers (HCDMs) and managed care professionals require education on the principles of immuno-oncology and the mechanisms of action behind these novel treatments. Furthermore, given increased focus on value-based benefit design, utilization management, and payer-led clinical interventions to address shortfalls in oncology practice, managed care stakeholders also have a need for information to effectively address the evolving paradigm of cancer treatment. This symposium will provide HCDMs and managed care professionals with the required education on the principles of immuno-oncology and the mechanisms of action behind these novel treatments.

Program Manager
Steven Casebeer, MBA
Steve.casebeer@impactedu.net

No fee registration: Click Here

Friday, April 24 | 6:00 am – 7:45 am


SS11:  Beta Thalassemia: A Look into Healthcare Utilization and Novel Treatment Advances | Room:  381

Provided by Pharmacy Times Continuing Education. Supported by independent educational grants from Celgene Corporation and bluebird bio. Continuing education credit available for pharmacists.

Program Description

β thalassemia describes a genetic defect where β-globin chain production is diminished or lost completely while simultaneously observing an excess of α-globin chains. As a result, the imbalance in globin chain synthesis causes red blood cell precursor destruction, also known as ineffective erythropoiesis. The body’s response to ineffective erythropoiesis and anemia is an increased production of erythropoietin, leading to erythroid hyperplasia, which may manifest as skeletal deformities, osteoporosis, and splenomegaly among other comorbidities. Severe disease left untreated or even undertreated results in the potential for growth retardation, potential cardiac enlargement, and sometimes severe cardiac failure. Red blood cell transfusions are the cornerstone of current therapy to maintain adequate hemoglobin levels. Lifelong transfusions are usually required every 2-5 weeks and include significant risks such as blood-borne infection (primarily hepatitis B and C in developing countries) and iron overload, as well as acute reactions. Emerging therapies may minimize the need for red blood cell transfusions. This live symposium features a clinical hematology pharmacist and a managed care expert in hematology to examine the pathophysiology of β thalassemia and its associated complications, explore current and emerging therapies, and characterize the clinical and economic burden.

Program Manager
Crissy Wilson
cwilson@pharmacytimes.com

No fee registration: Click Here

SS12:  Navigating a Changing Landscape in TNBC: Managed Care Strategies in the Era of Immunotherapy | Room:  382

Provided by Creative Educational Concepts. Supported by an independent educational grant from Merck & Co., Inc. Continuing education credit available for pharmacists and physicians.

Program Description

Symposium attendees will gain insights into the molecular heterogeneity and diverse clinical features of TNBC, a condition which comprises 15-20% of all breast cancer cases, and has historically had limited treatment options, been associated with earlier age of onset, more aggressive disease course, and poorer prognosis. Attendees will also review the current state of immunotherapy research in TNBC, including completed and ongoing clinical trials across various stages of the disease continuum, the approval of emerging agents and indications throughout the treatment calculus, and prospective avenues of research focus, such as the identification of predictive novel biomarkers to help guide treatment decisions. Finally, using an interactive, case-based approach, this symposium will comprehensively evaluate current challenges in TNBC management and examine adaptive strategies that managed care and specialty pharmacists can employ to optimize patient outcomes in the era of immunotherapy.

Program Manager
Ashley Lilly
www.ceconcepts.com

No fee registration: Click Here

For more information please contact Maria Miranda at mmiranda@amcp.org